Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma

Transarterial chemoembolization (TACE) is a widely used treatment for hepatocellular carcinoma. In order to maximize its therapeutic efficacy, doxorubicin-loaded drug-eluting beads have been developed to deliver higher doses of the chemotherapeutic agent and to prolong contact time with the tumor. T...

Full description

Saved in:
Bibliographic Details
Published in:Journal of hepatology Vol. 57; no. 6; pp. 1244 - 1250
Main Authors: Song, Myeong Jun, Chun, Ho Jong, Song, Do Seon, Kim, Hee Yeon, Yoo, Sun Hong, Park, Chung-Hwa, Bae, Si Hyun, Choi, Jong Young, Chang, U Im, Yang, Jin Mo, Lee, Hae Giu, Yoon, Seung Kew
Format: Journal Article
Language:English
Published: Kidlington Elsevier B.V 01.12.2012
Elsevier
Subjects:
Aged
Antibiotics, Antineoplastic - administration & dosage
Antibiotics, Antineoplastic - adverse effects
Biological and medical sciences
Carcinoma, Hepatocellular - mortality
Carcinoma, Hepatocellular - therapy
Chemoembolization, Therapeutic
Conventional TACE
DC bead® TACE
Disease Progression
Doxorubicin - administration & dosage
Doxorubicin - adverse effects
Female
Gastroenterology and Hepatology
Gastroenterology. Liver. Pancreas. Abdomen
Humans
Liver Neoplasms - mortality
Liver Neoplasms - therapy
Liver. Biliary tract. Portal circulation. Exocrine pancreas
Male
Medical sciences
Middle Aged
Retrospective Studies
Survival Rate
Time to progression
Treatment response
Tumors
PR
RECIST
BCLC
TACE
cTACE
Time to progression
HCC
DC bead
Treatment response
RFA
Conventional TACE
CR
SD
PD
RCTs
DEBDOX
DC bead® TACE
progressive disease
Response Evaluation Criteria in Solid Tumors
drug-eluting bead
conventional TACE
stable disease
DC bead® loaded with doxorubicin
randomized controlled studies
transarterial chemoembolization
partial response
hepatocellular carcinoma
Barcelona Clinic for Liver Cancer
complete response
radiofrequency ablation
Antineoplastic agent
Prognosis
Hepatic disease
Hepatocellular carcinoma
Doxorubicin
Isomerases
Gastroenterology
Evolution
DNA topoisomerase (ATP-hydrolysing)
Enzyme
Enzyme inhibitor
Instrumentation therapy
Topoisomerase II inhibitor
Malignant tumor
Antibiotic
Digestive diseases
Embolization
Anthracyclins
Comparative study
Cancer
Chemoembolization
ISSN:0168-8278, 1600-0641, 1600-0641
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Transarterial chemoembolization (TACE) is a widely used treatment for hepatocellular carcinoma. In order to maximize its therapeutic efficacy, doxorubicin-loaded drug-eluting beads have been developed to deliver higher doses of the chemotherapeutic agent and to prolong contact time with the tumor. The purpose of this study was to evaluate the efficacy and safety of drug-eluting bead (DC bead®) TACE in comparison with conventional TACE (cTACE). A total of 129 patients who underwent TACE between August 2008 and February 2011 were enrolled. We compared HCC patients who underwent TACE with DC bead® (n=60) to controls who received cTACE (n=69). The primary end points were treatment response and treatment-related adverse events. The secondary end point was time to progression. The treatment response in the DC bead® group was significantly higher than that of the cTACE group (p<0.001). The time to progression was significantly better in the DC bead® group than in the cTACE group (11.7 and 7.6months, respectively, p=0.018). Subgroup analysis showed that in intermediate-stage HCC, DC bead® treatment resulted in a significantly better treatment response and longer time to progression than cTACE (p<0.001 and 0.038, respectively). However, there was no statistically significant difference in liver toxicity between the DC bead® and cTACE group (p>0.05). TACE with DC bead® showed better treatment response and delayed tumor progression compared with cTACE. There was no significant difference in hepatic treatment-related toxicities. DC bead® TACE thus appears to be a feasible and promising approach to the treatment of HCC.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:0168-8278
1600-0641
1600-0641
DOI:10.1016/j.jhep.2012.07.017